Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 3031-3040 Newer>

The Motley Fool July 25, 2006 Brian Lawler	Strike Two for Encysive The FDA still won't quite give Thelin a thumbs-up. For now, Encysive investors can only sit and wait.
The Motley Fool July 24, 2006 Stephen D. Simpson	Can Schering-Plough Continue to Shine? Cost-cutting and cholesterol drug sales continue apace, but is the company vulnerable? Investors, take note.
The Motley Fool July 21, 2006 Brian Lawler	Sepracor Stays Alert Insomnia drug Lunesta's sales growth is anything but sleepy. Despite the shares' ups and downs, Sepracor's most recent earnings suggest that its performance remains admirably steady.
The Motley Fool July 21, 2006 Stephen D. Simpson	Stryker and the Terror of the Unknown This has been a pretty bad year to be a good medical technology company. Fears about future pricing and the DOJ investigation keep a lid on the entire sector. So, what about that future for Stryker? Investors, take note.
The Motley Fool July 20, 2006 Brian Lawler	No Surprises From ImClone ImClone's lead product experienced strong revenue growth in the second quarter. But biotech investing is fraught with risk. Investors, take note.
The Motley Fool July 18, 2006 Stephen D. Simpson	Can J&J Do Better Than GDP? Investors and analysts are obsessed with growth, but Johnson & Johnson isn't.
The Motley Fool July 18, 2006 Stephen D. Simpson	Survival of the Forest New products and a favorable patent ruling give Forest Labs a boost. Investors, this stock remains one to watch.
Fast Company July 2006 Chuck Salter	Labs on a Chip A powerful portable biosensor that will be easy to use, flexible, and capable of performing multiple diagnostic tests is expected to be available in a "couple of years."
The Motley Fool July 17, 2006 Stephen D. Simpson	Medtronic's Evolutionary Revolution Step by step, Medtronic may change how diabetes is treated.
Reactive Reports Issue 57	Interview with Andrew Lemon With a background in Chemistry and a keen sense of business, this co-found of The Edge Software Consultancy helps global pharmaceutical companies increase the efficiency and productivity of their software tools.
<Older 3031-3040 Newer> Return to current articles.